

**NEW!**

The Pharma Industry

Search Engine:

Download the PharmaLiveSearch.com toolbar

Corporate Access



Account Login



Search



How it Works

NEWS

BLOGS

MED AD NEWS

R&D DIRECTIONS

SPECIAL REPORTS

INFORMATION TOOLS

NEWSLETTERS

CONFERENCES

Business

Marketing & Advertising

Therapeutics

R&D News

FDA News

Conference News

People

TRIAL RESULTS

HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market

HemCon Medical Technologies, Inc. Announces Promising Results from Live Nail Infection Anti-Fungal Study Technology Platform Offers Tested Solution to Fungal Care Market

PORTLAND, Ore. – Feb. 5, 2009 – HemCon Medical Technologies today announced preliminary data resulting from an independent, realistic study to treat and kill the *T. Rubrum* organism which causes Onychomycosis, a common fungal nail infection. The studies were conducted using a formulation based on HemCon's newest proprietary platform technology available for license, Mycosinate™ (formerly known as A31S), that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.

Independent testing of HemCon's topical formulation, Mycosinate™ for the treatment of Onychomycosis was analyzed by MedPharm Ltd.'s ChubTur® system using infected distal human nails. This system tests the ability to kill the *T. Rubrum* infecting the human nails over a period of time. HemCon's formulation was evaluated against a placebo. In preliminary data, HemCon's Mycosinate™ killed off the organism within a 14 day treatment plan. Additional testing to compare kill rates at three and seven day intervals will be completed by April 2009.

Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment products is estimated at approximately US\$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis is responsible for nearly 50 percent of reported cases.

"Our third, most accurate anti-fungal test yet, combined with earlier successes in nail penetration and human safety, affirms the exceptional promise of Mycosinate™ to provide effective relief for the millions of Americans afflicted with fungal nail infections," said John W. Morgan, CEO of HemCon. "As HemCon continues to offer new technologies for commercialization that promote safe, effective healing, we pledge to work in tandem with our partners to offer patients solutions that improve lives on a global scale."

About HemCon Medical Technologies Inc. HemCon Medical Technologies Inc., is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon dressing used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is



User Tools

Subscriber registration

Purchase a subscription

Forget your password

Need help?

Your account details

Order back issues

Renew subscription

Advertise



leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit www.hemcon.com

###

Public Relations Contact: Nicole Elovitz HemCon Medical Technologies Inc. 503-245-0459
nicole@hemcon.com



[Printer Friendly Version](#)



[Forward to a Friend](#)

Get Instant Access to our News Archive

For more than 20 years, executives like you have relied on Canon Communications Pharmaceutical Media Group for the business, marketing, and clinical research information needed to make informed business decisions. **InfoPass** gives you access to an array of integrated information services – information that is critical to your success and the success of your organization.

[Login or activate](#) your InfoPass Account now!

[about us](#) | [advertise](#) | [contact us](#) | [home](#)
[terms of use](#) | [privacy](#) | [copyright](#) | [site map](#)

©2009 Canon Communications Pharmaceutical Media Group